BIOTICSAI NAVIGATES FDA APPROVAL, FUNDRAISING

Speaking on Build Mode, Bustami outlined the challenges of operating in a sector where regulatory requirements significantly impact development timelines and capital needs. The CEO emphasized the importance of maintaining team morale through lengthy approval processes. Healthcare startups face unique pressures: regulatory delays can stretch fundraising cycles, and uncertainty around FDA decisions affects both investor confidence and employee retention. Bustami highlighted key strategies for managing these pressures, including transparent communication with stakeholders about regulatory timelines and setting realistic milestones that account for agency review periods. Fundraising in regulated industries requires investors comfortable with extended development cycles. BioticsAI's approach involves demonstrating clear pathways to regulatory approval while showing traction in parallel areas that don't require FDA clearance. The conversation underscored a broader reality: healthcare startups must build operational resilience into company culture. Success depends not just on technology, but on navigating bureaucratic processes without losing momentum or talent.